May 5, 2026 04:05PM
Feb 10, 2026 04:05PM
Jan 12, 2026 04:05AM
Jan 11, 2026 04:00PM
Dec 12, 2025 10:31AM
Nov 4, 2025 04:27PM
Nov 4, 2025 04:05PM Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update
Jul 28, 2025 04:05PM
May 13, 2025 04:07PM
Feb 11, 2025 04:05PM
Jan 12, 2025 04:00PM
Oct 29, 2024 04:05PM
Aug 6, 2024 04:05PM
Apr 30, 2024 04:05PM Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update
Feb 6, 2024 04:05PM
Jan 8, 2024 05:25AM
Jan 7, 2024 04:00PM
Sep 12, 2023 08:03AM
Sep 12, 2023 08:00AM
Aug 1, 2023 04:05PM
May 9, 2023 04:05PM Exelixis Announces First Quarter 2023 Financial Results and Provides Corporate Update
Apr 13, 2023 04:11PM
Apr 13, 2023 04:11PM
Mar 20, 2023 07:00AM
Mar 20, 2023 07:00AM
Feb 7, 2023 04:05PM
Jan 9, 2023 04:58AM
Jan 8, 2023 04:00PM Exelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023
Jan 4, 2023 09:00AM
Dec 1, 2022 06:23AM
Nov 3, 2022 08:05AM
Nov 3, 2022 08:00AM
Nov 1, 2022 04:08PM
Nov 1, 2022 04:07PM
Nov 1, 2022 04:07PM Exelixis and Sairopa Establish Exclusive Clinical Development Collaboration and Option Agreement to Develop ADU-1805, a Potentially Best-in-Class Monoclonal Antibody Targeting SIRPĪ±
Nov 1, 2022 04:06PM
Nov 1, 2022 04:05PM
Aug 9, 2022 04:05PM
Jul 7, 2022 12:00AM
Jun 16, 2022 12:00AM
May 10, 2022 04:05PM
Apr 13, 2022 04:06PM Exelixis (EXEL) Announces Charles Cohen, Ph.D., to Retire from Board of Directors
Apr 13, 2022 04:05PM
Feb 17, 2022 04:05PM
Jan 10, 2022 05:48AM
Jan 9, 2022 04:00PM
Jan 6, 2022 08:00AM
Nov 2, 2021 04:05PM
Oct 14, 2021 08:30AM Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes
Oct 14, 2021 08:04AM

1,160,146 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All